Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Interferons hepatitis

Cytokines and biological response modifiers represent a broad class of therapeutic agents that modify the hosts response to cancer or cancer therapies. The enormous body information about their clinical uses and their side effects is beyond the scope of this essay that can only give illustrative examples. For an up-to-date information the reader can resort to reference [5]. As many as 33 different interleukins are known and the list continues to grow IL-2 used in the treatment of kidney cancer is one example. Interferon alpha is used for chronic myelogenous leukeia, hairy cell leukaemia and Kaposi s sarcoma. Interferons are also used in the treatment of chronic infections such as viral hepatitis. Tumor necrosis factor (alpha), G/GM/M-CSF, and several other cellular factors are used in treatment of various cancers. Many of these cytokines produce serious side effects that limit their use. [Pg.268]

Interferon alfacon-1 (Inferax ), interferon alfa-2b (IntronA ), and interferon alfa-2a (Roferon -A) are applied in the treatment of chronic hepatitis B and C and some malignancies, especially hairy cell leukemia. IFN-a proteins induce the expression of antiviral, antiproliferative and immunomodulatory genes. [Pg.411]

Hepatocellular carcinoma (HCC) develops in patients with chronic liver diseases associated with hepatitis B and hepatitis C vims infections with high incidences. Here, an acyclic retinoid has been shown to suppress the posttherapeutic recurrence after interferon-y or glycerrhicin treatment in cirrhotic patients who underwent curative treatment of preceding tumors. The retinoid induced the disappearance of serum lectin-reactive a-fetoprotein (AFP-L3), a tumor marker indicating the presence of unrecognizable tumors in the remnant liver, suggesting a deletion of such minute (pre)malignant clones (clonal deletion). As a molecular mechanism of the clonal deletion, a novel mechanism of... [Pg.1076]

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet 358 958-965... [Pg.23]

Abstract In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN) by Isaacs and Lindemnann. Subsequently, the IFN-a gene was cloned, fully sequenced and IFN-a was produced in recombinant form. Recombinant IFN-a is now used as the basis for treatment of chronic hepatitis C virus infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, although with less success. The antiviral mechanisms of IFNs are reviewed in this chapter as well as the utility of IFNs in the treatment of persistent viral infections. [Pg.204]

Akarca US, Ersoz G, Gunsar F, Karasu Z, Santas E, Yuce G, Batur Y (2004) Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther 9 325-334... [Pg.230]

Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, FisceUa M, Yu R, Osborn BE, Cronin PW, Ereimuth WW, McHutchison JG, Subramanian GM (2006) A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 44 671-678... [Pg.230]

Bain VG, Marotta P, Kaita K, Yoshida E, Swain MG, Bailey R, Neumann AU, Cronin PW, McHutchison JG, Pulkstenis E, Subramanian GM (2007) Comparable antiviral response rates with albumin interferon alpha-2b dosed at Q2W or Q4W intervals in naive subjects with genotype 2 or 3 chronic hepatitis C. J Hepatol 46 S7... [Pg.230]

Balan V Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfleld RR, Davis GL, Neumann AU, Osborn BE, Ereimuth WW, Subramanian GM (2006) A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy, Antivir Ther 11 35 5... [Pg.230]

Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, PeUiceUi A, Grisorio B, Barbarini G (1999) Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Scand J Gastroenterol 34 928-933... [Pg.230]

Bocher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, Mudter J, Lohr HF, Galle PR (2006) Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int 26 319-325... [Pg.231]

Bortolotti F, Jara P, Barbera C, Gregorio GV, Vegnente A, Zancan L, Hierro L, CriveUaro C, Vergani GM, lorio R, Pace M, Con P, Gatta A (2000) Long term effect of alpha interferon in children with chronic hepatitis B. Gut 46 715-718... [Pg.231]

BriUanti S, Garson J, FoU M, Whitby K, Deaville R, Masci C, MigUoU M, Barbara L (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107 812-817... [Pg.231]

CanbakanB, SenturkH, TabakF, Akdogan M, Tahan V, Mert A, Sut N, Ozaras R, Midilli K, Ozbay G (2006) Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis a randomized trial. J Gastroenterol Hepatol 21 657-663... [Pg.231]

Carreno V, MarceUin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jimenez FJ, Quiroga JA (1999) Retreatment of chrome hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. Hepatology 30 277-282... [Pg.231]

Castro A, Suarez D, Inglada L, CarbaUo E, Dominguez A, Diago M, Such J, Del Olmo JA, Perez-Mota A, Pedreira J, Quiroga JA, Carreno V (1997) Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C. J Interferon Cytokine Res 17 27-30... [Pg.231]

De Rosa EG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Veronese L, Raiteri R, CaUeri G, Di Perri G (2006) The early HCV RNA dynamics in patients with acute hepatitis C treated with pegylated interferon-alpha2b. Antivir Ther 11 165-171 Di Bisceglie A (1997) Hepatitis D virus. Marcel Dekker, NY... [Pg.232]

Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Jomura H, Habu D, Sakaguchi H, Takeda T, Kawada N, Seki S, Shiomi S, Koh N, Nishiguchi S (2007) Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection. J Interferon Cytokine Res 27 201-207... [Pg.232]

Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, Heintges T, Haussinger D (2006) Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 26 805-810... [Pg.232]

Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, Gibo Y, Caruso L, Scaccabarozzi S, Criscuolo D et al (1994) Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 330 88-94... [Pg.233]

Earci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, Serra G, Lai ME, Loy M, Caruso L, Desmet V, PurceU RH, Balestrieri A (2004) Long-term benefit of interferon alpha therapy of chronic hepatitis D regression of advanced hepatic fibrosis. Gastroenterology 126 1740-1749... [Pg.233]

Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL (2006b) Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101 297-303... [Pg.233]

Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, Bartenschlager R (2002) Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35 694-703... [Pg.233]

Gunsar E, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, liter T, Batur Y (2005) Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 10 721-726 Habersetzer E, Boyer N, MarceUin P, Badly F, Ahmed SN, Alam J, Benhamou JP, Trepo C (2000) A pdot study of recombinant interferon beta-la for the treatment of chronic hepatitis C. Liver 20 437 41... [Pg.234]

Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S (2007) Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 126 245-249 Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di BiscegUe A, Peters M, Waggoner JG, Park Y, Jones EA (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315 1575-1578 Horiike N, Onji M (2003) Combination therapy with interferon-alpha and ribavirin as im-munomodulators in patients with chronic hepatitis C. J Gastroenterol 38 302-304... [Pg.234]

See other pages where Interferons hepatitis is mentioned: [Pg.312]    [Pg.419]    [Pg.312]    [Pg.419]    [Pg.238]    [Pg.238]    [Pg.238]    [Pg.235]    [Pg.200]    [Pg.32]    [Pg.27]    [Pg.42]    [Pg.47]    [Pg.79]    [Pg.108]    [Pg.230]    [Pg.231]    [Pg.231]    [Pg.232]    [Pg.232]    [Pg.232]    [Pg.234]    [Pg.234]    [Pg.235]    [Pg.235]    [Pg.235]   
See also in sourсe #XX -- [ Pg.179 , Pg.180 , Pg.181 , Pg.182 ]



SEARCH



Alpha-interferon hepatitis treatment

Hepatitis interferon therapy

Hepatitis interferon treatment

Hepatitis pegylated interferon

Interferon therapy in chronic hepatitis

Interferon therapy in hepatitis

Viral hepatitis, interferons

© 2024 chempedia.info